Osteoporosis without pathological fractures
ICD-10 M81 · ICD-11 FB83.1

High-Risk Osteoporosis When First-Line Anti-Resorptive Therapy Has Not Met Bone Density Targets

Patient scenario

This protocol applies to patients with osteoporosis at high risk of fracture — defined by a bone mineral density T-score of ≤−2.5 at any site, or a FRAX 10-year major osteoporotic fracture probability of ≥20% — and who do not have very-high-risk features (no multiple vertebral fractures, no fragility fracture within the previous two years).

Why this step is needed — prior treatment fell short

First-line anti-resorptive therapy — oral bisphosphonates (alendronate, risedronate), intravenous zoledronate, or denosumab, combined with calcium, vitamin D, and weight-bearing exercise — did not achieve the required bone mineral density response: a ≥0.2-unit (3%) improvement in total hip T-score and a ≥0.5-unit (6%) improvement in lumbar spine T-score over three years.

When these bone density targets are not reached, a structured escalation is indicated.

Next-step treatment approach (partial)

The next step involves a sequential transition to an osteoanabolic agent — a bone-building therapy — followed by a return to anti-resorptive therapy to consolidate and extend the gains achieved.

Agent selection, phase duration, and the full treatment algorithm remain in the complete protocol below.

Therapeutic goal

Continued increase in total hip, femoral neck, and lumbar spine bone mineral density toward the personalised T-score target over three years.

Instant Access to Structured Evidence-Based Regimens
References

DOI: 10.1136/bmj‐2024‐081250

  1. All recommend anti-resorptives as first line therapy for patients at high risk and osteoanabolics for those at very high risk.
  2. AACE, Endocrine Society, and BHOF recommend a T-score based strategy when T ≤−2.5 at any site or a fixed risk threshold when T-score is between −2.5 and −1.0 if FRAX 10 year MOF is ≥20% or 10 year HF is ≥3%.
  3. In practice, anti-resorptive-to-osteoanabolic transitions are common as osteoanabolics became available only in recent years and owing to cost constraints of osteoanabolics.
  4. Experts recommend an improvement in total hip T-score of at least 0.2 units (3%) and in lumbar spine T-score of at least 0.5 units (6%), on the basis of reasonable chances of attaining such increments over three years by most therapies, including anti-resorptives.
View source ↗